In Brief: Medtronic/InStent
This article was originally published in The Gray Sheet
Executive SummaryMedtronic/InStent: Complete $200 mil. stock merger following approval by InStent shareholders. Under terms of the deal, for which an agreement was announced in March ("The Gray Sheet" April 1, p. 11), Medtronic will exchange 0.3833 shares of its stock for each of the approximately 10 mil. InStent shares, plus options outstanding...
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.